Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (11915)	9/20/2005 9:28:49 AM
From: Joseph B. Schmidt	Respond to of 23958

Dendreon to Webcast Presentation at UBS Global Life Sciences Conference Sep 20, 2005 9:00:00 AM SEATTLE, Sept. 20 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the UBS Global Life Sciences Conference at the Grand Hyatt in New York City on Tuesday, September 27 at 11:00 a.m. ET. The presentation will be audio webcast live and available for replay from the Investors/Webcast section of Dendreon's website, www.dendreon.com, or through the UBS website, www.ibb.ubs.com. The replay of the presentation will begin 3 hours after the actual presentation time and will be available until October 29, 2005. Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the development of innovative cancer treatments. In addition to its immunotherapies in clinical and preclinical development for a variety of cancers, Dendreon's product pipeline also includes monoclonal antibody and small molecule product candidates. Dendreon has research and development alliances with Genentech, Inc., Abgenix, Inc. and Dyax Corp. For more information about the company and its programs, visit www.dendreon.com. Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. SOURCE Dendreon Corporation ---------------------------------------------- Monique M. Greer Sr. Director Corporate Communications of Dendreon Corporation 206-829-1500